Prevalence and clinical significance of prostate cancer among 12,682 men with normal digital rectal examination, low PSA levels (≤4 ng/ml) and percent free PSA cutoff values of 15 and 20%

Urologia Internationalis

Volumn 78, Issue 4, 2007, Pages 308-312

  Pepe, Pietro ^a   Panella, Paolo ^a   Savoca, Francesco ^a   Cacciola, Antonio ^a   D'Arrigo, Letterio ^a   Dibenedetto, Giuseppe ^b   Pennisi, Michele ^a   Aragona, Francesco ^a  

^a CANNIZZARO HOSPITAL   (Italy)

^b Urology Unit   (Italy)

Author keywords

Early diagnosis, prostate cancer; Extended prostate biopsy; Prostate cancer; Radical prostatectomy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER EPIDEMIOLOGY; CANCER LOCALIZATION; CANCER SURGERY; CASE FINDING; CLINICAL PROTOCOL; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; GLEASON SCORE; HUMAN; HUMAN TISSUE; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; SURGICAL TECHNIQUE;

ADULT; AGED; DIGITAL RECTAL EXAMINATION; HUMANS; MALE; MIDDLE AGED; PREVALENCE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 34248163980     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000100833     Document Type: Article

References (34)

1. Gann P, Hennekens C, Stampfer M: A prospective evaluation of plasma PSA for detection of prostate cancer. JAMA 1995;273:289-294.
2. Thompson I, Pauler D, Goodman P, Tangen C, Lucia M, Parnes H, Minasian L, Ford L, Lippman S, Crawford E, Crowley J, Coltman C Jr: Prevalence of prostate cancer among men with a PSA level ≤ 4.0 ng per milliliter. N Engl J Med 2004;350:2239-2246.
3. Aragona F, Pepe P, Motta M, Saita A, Raciti G, La Rosa P, et al: Incidence of prostate cancer in Sicily: results of a multicenter case-findings protocol. Eur Urol 2005;47:569-574.
4. Ravery V, Golblatt L, Royer B, Blanc E, Tonblanc M, Boccon-Gibod L: Extensive biopsy protocol improves the detection rate of prostate cancer. J Urol 2000;164:393-396.
5. Catalona W, Smith D, Ornstein D: Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/ml and benign prostate examination: enhancement of specificity with free PSA measurements. JAMA 1997;277:1452-1455.
6. Djavan B, Zlotta A, Kratzik C, Remzi M, Seitz C, Schulman C, Marberger M: PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early prostate cancer detection in men with total PSA of 2.5 to 4 ng/ml. Urology 1999;54:517-522.
7. Okihara K, Fritsche H, Ayala A, Johnston D, Allard W, Babaian R: Can complexed PSA and prostatic volume enhance prostate cancer detection in men with total PSA between 2.5 and 4.0 ng/ml. J Urol 2001;165:1930-1936.
8. Babaian R, Johnston D, Naccarato W: The incidence of prostate cancer in a screening population with a serum PSA between 2.5 and 4.0 ng/ml: relation to biopsy strategy. J Urol 2001;165:757-760.
9. Krumholtz J, Carvalhal G, Ramos C, Smith D, Thorson P, Yan Y, Humphrey P, Roehl K, Catalona W: PSA cutoff of 2.6 ng/ml for prostate cancer screening is associated with favorable pathologic tumor features. Urology 2002;60:469-473.
10. Horninger W, Berger A, Rogatsch H, Gschwendtner A, Steiner H, Niescher M, Klocker H, Bartsch G: Characteristics of prostate cancers detected at low PSA levels. Prostate 2004;58:232-237.
11. Epstein J, Walsh P, Carmichael M: Pathological and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271:368-374.
12. Smith R, Malkowicz S, Whittington R, Van Arsdalen K, Tochner Z, Wein A: Identification of clinically significant prostate cancer by PSA screening. Arch Intern Med 2004;164:1227-1230.
13. Schroeder F, van der Cruijsen-Koeter I, de Koning H, Vis A, Hoedemaeker RF, Kranse R: Prostate cancer detection at low PSA. J Urol 2000;163:806-812.
14. Hugosson J, Aus G, Lilja H, Lodding P, Pihl C: Results of a randomized, population-based study of biennial screening using serum PSA measurement to detect prostate carcinoma. Cancer 2004;100:1397-1405.
15. Sokoloff M, Yang X, Fumo M, Mhoon D, Brendler C: Characterizing prostatic adenocarcinomas in men with a serum PSA level of <4 ng/ml. BJU Int 2004;93:499-502.
16. Horninger W, Volgger H, Rogatsch H, Gschwendtner A, Bartsch G: Consideration of low PSA cut-off levels to optimize the detection of curable prostate cancer. Eur Urol 2001;39(Suppl 4):43-46.
17. Kuller L, Thomas A, Grandits G, Neaton J: Elevated PSA levels up to 25 years prior to death from prostate cancer. Cancer Epidemiol Biomarkers Prev 2004;13:373-377.
18. Carter H, Epstein J, Chan D: Recommended PSA testing intervals for the detection of curable prostate cancer. JAMA 1997;277:1456-1460.
19. Antenor J, Han M, Roehl K, Nadler R, Catalona W: Relationship between initial PSA level and subsequent prostate cancer detection in a longitudinal screening study. J Urol 2004;172:90-93.
20. Punglia R, D'Amico A, Catalona W, Roehl K, Kuntz K: Effect of verification bias on screening for prostate cancer by measurement of PSA. N Engl J Med 2003;349:335-342.
21. Stamey T, Caldwell M, McNeal J, Nolley R, Hemenez M, Downs J: The PSA era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol 2004;172:1297-1301.
22. Matlaga B, Eskew L, McCullough D: Prostate biopsy: indications and technique. J Urol 2003;169:12-19.
23. Gann P, Ma J, Catalona W: Strategies combining total and percent free PSA for detecting prostate cancer: a prospective evaluation. J Urol 2002;167:2427-2434.
24. Hoffman R, Clanon D, Littenberg B, Frank J, Peirce J: Using the free-to-total PSA ratio to detect prostate cancer in men with nonspecific elevations of PSA levels. J Gen Intern Med 2000;15:739-748.
25. Tornblom M, Norming U, Adolfsson J, Becker C, Abrahamsson P, Lilja H, Gustafsson O: Diagnostic value of per cent free PSA: retrospective analysis of a population-based screening study with emphasis on men with PSA levels less than 3.0 ng/ml. Urology 1999;53:945-950.
26. Raaijmakers R, Blijenberg B, Finlay J: Prostate cancer detection in the PSA range of 2.0 to 3.9 ng/ml: value of percent free PSA on tumor detection and tumor aggressiveness. J Urol 2004;171:2245-2249.
27. Roehl K, Antenor J, Catalona W: Robustness of free PSA measurements to reduce unnecessary biopsies in the 2.6 to 4.0 ng/ml range. J Urol 2002;168:922-925.
28. Stamey T, Freiha F, McNeal J, Redwine E, Whitemore A, Schmid H: Localized prostate cancer: relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 1993;71(Suppl):933-938.
29. Epstein J, Walsh P, Carmichael M: Pathological and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271:368-374.
30. Humphrey P: Gleason grading and prognostic factors in carcinoma of the prostate. Mod Pathol 2004;17:292-306.
31. Lattouf J, Saad F: Gleason score on biopsy: is it reliable for predicting the final grade on pathology? BJU Int 2002;90:694-697.
32. Sved P, Gomez P, Manoharan M, Jim S, Soloway M: Limitations of biopsy Gleason grade: implications for counseling patients with biopsy Gleason score 6 prostate cancer. J Urol 2004;172:98-102.
33. Epstein J, Potter S: The pathological interpretation and significance of prostate needle biopsy findings: implications and current controversies. J Urol 2001;166:402-410.
34. Djavan B, Milani S, Fong Y: Benign positive margins after radical prostatectomy means a poor prognosis - pro. Urology 2005;65:218-220.